作者
Valentina Pita-Grisanti,Ericka Vélez-Bonet,Kaylin Chasser,Zachary Hurst,Alexus Liette,Grace Vulic,Kelly Dubay,Ali Lahooti,Niharika Badi,Olivia Ueltschi,Kristyn Gumpper,Hsiang‐Yin Hsueh,Ila Lahooti,Myrriah Chavez-Tomar,Samantha Terhorst,Sue E. Knoblaugh,Lei Cao,Wei Huang,Christopher C. Coss,Thomas A. Mace,Fouad Choueiry,Alice Hinton,Stacey Culp,Jennifer M. Mitchell,Rosemarie Schmandt,Michaela Onstad Grinsfelder,Karen Basen‐Engquist,Zobeida Cruz‐Monserrate
摘要
Abstract Obesity is a risk factor for pancreatic ductal adenocarcinoma (PDAC), a deadly disease with limited preventive strategies. Lifestyle interventions to decrease obesity represent a potential approach to prevent obesity-associated PDAC. Here, we examined whether decreasing obesity through physical activity (PA) and/or dietary changes could decrease inflammation in humans and prevent obesity-associated PDAC in mice. Comparison of circulating inflammatory-associated cytokines in subjects (overweight and obese) before and after a PA intervention revealed PA lowered systemic inflammatory cytokines. Mice with pancreatic-specific inducible KrasG12D expression were exposed to PA and/or dietary interventions during and after obesity-associated cancer initiation. In mice with concurrent diet-induced obesity (DIO) and KrasG12D expression, the PA intervention led to lower weight gain, suppressed systemic inflammation, delayed tumor progression, and decreased pro-inflammatory signals in the adipose tissue. However, these benefits were not as evident when obesity preceded pancreatic KrasG12D expression. Combining PA with diet-induced weight loss (DI-WL) delayed obesity-associated PDAC progression in the genetically engineered mouse model, but neither PA alone nor combined with DI-WL or chemotherapy prevented PDAC tumor growth in orthotopic PDAC models regardless of obesity status. PA led to upregulation of IL-15ra in adipose tissue. Adipose-specific overexpression of IL-15 slowed PDAC growth but only in non-obese mice. Overall, our study suggests that PA alone or combined with DI-WL can reduce inflammation and delay obesity-associated PDAC development or progression. Lifestyle interventions that prevent or manage obesity or therapies that target weight loss-related molecular pathways could prevent progression of PDAC.